NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Research this for yourself: The successful global P3 DCVax trial was conducted at 94 sites worldwide and was designed and led by two CLINICAL TRIAL EXPERTS, both who have been directly supported by their respective government’s regulators. The support of regulators is ongoing.

Dr. Linda Liau is a world-renowned neuro-oncologist, surgeon, and educator at UCLA where she is also the chair of the department of neurosurgery. As her paper on DCVax moves through the independent peer review process, it is interesting to note that she was once the editor-in-chief of a neuro-oncology medical journal.

https://www.uclahealth.org/providers/linda-liau

https://doi.org/10.3171/2020.12.FOCUS20954

https://soc-neuro-onc.org/

Across the pond from Dr. Liau, Dr. Ashkan was the chief investigator of the DCVax trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.

https://www.kcl.ac.uk/people/keyoumars-ashkan

https://virtualtrials.org/dcvax.cfm

Fact check:
These are the “types” that are posted on clinicaltrials.gov: “investigational” and “observational.” Either of these could be adaptive. To date, “adaptive” is not a distinct and separate “type” for any clinical trial in the U.S. in terms of the nature of studies as they are currently registered on the NIH clinical trial registry.

“Type”
describes the nature of a
clinical study. Study types
include interventional studies
(also called clinical trials),
and observational studies
(including patient registries)
and expanded access.

https://clinicaltrials.gov/ct2/about-studies/learn
https://virtualtrials.org/dcvax.cfm